Log in

Relevant bibliographies by topics / BONE CEMENTS/therapeutic use

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'BONE CEMENTS/therapeutic use'

Author: Grafiati

Published: 4 June 2021

Last updated: 9 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'BONE CEMENTS/therapeutic use.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "BONE CEMENTS/therapeutic use"

1

Catena, Vittorio, Guilhem Roubaud, Amandine Crombe, Michèle Kind, Jean Palussiere, and Xavier Buy. "Image-Guided Bone Consolidation in Oncology." Seminars in Interventional Radiology 35, no. 04 (October 2018): 221–28. http://dx.doi.org/10.1055/s-0038-1669468.

Full text

Abstract:

AbstractOccurrence of bone metastases is a common event in oncology. Bone metastases are associated with pain, functional impairment, and fractures, particularly when weight-bearing bones are involved. Management of bone metastases has been improved by the development of various interventional radiology consolidation techniques. Cementoplasty is based on injection of acrylic cement into a weakened bone to reinforce it and to control pain. This minimally invasive technique has proven its efficacy for flat bone submitted to compression forces. However, resistance to torsion forces is limited and, thus, treatment of long bones should be considered with caution. In recent years, variant techniques of percutaneous bone consolidation have emerged, including expansion devices for vertebral augmentation and percutaneous screw fixation for pelvic bone and proximal femur tumors. Research projects are ongoing to develop drug-loaded cements to use them as therapeutic vectors. However, release of drugs is still poorly controlled and conventional polymethylmethacrylate cement remains the gold standard in oncology. Image-guided consolidation techniques enhance the array of treatments in bone oncology. Multidisciplinary approach is mandatory to select the best indications.

APA, Harvard, Vancouver, ISO, and other styles

2

Ford, Samuel E., and J. Kent Ellington. "Management of Distal Tibial Metaphyseal Bone Defects With an Intramedullary Nitinol Scaffold: A Novel Technique." Foot & Ankle Specialist 10, no. 4 (November 21, 2016): 368–71. http://dx.doi.org/10.1177/1938640016679708.

Full text

Abstract:

Difficult problems that are faced when reconstructing severe pilon fractures include filling metaphyseal defects and supporting an impacted, multifragmented articular surface. Supplements to plate fixation currently available in a surgeon’s armamentarium include cancellous bone autograft, structural bone allograft, demineralized bone matrix, and calcium-based cements. Cancellous autograft possesses limited inherent mechanical stability and is associated with graft site morbidity. Structural allografts incorporate inconsistently and are plagued by late resorption. Demineralized bone matrix also lacks inherent structural stability. Calcium phosphate cements are not rigidly fixed to bone unless fixation is applied from cortical bone or through a plate, which must be taken into consideration when planning fixation. The Conventus DRS (Conventus Orthopaedics, Maple Grove, MN) implant is an expandable nitinol scaffold that takes advantage of the elasticity and shape memory of nitinol alloy. Once deployed and locked, it serves as a stable intramedullary base for fragment-specific periarticular fracture fixation, even in the face of metaphyseal bone loss. Two cases of successful implant use are presented. In both cases, the implant is used to fill a metaphyseal void and provide stable articular support to the distal tibial plafond. Levels of Evidence: Therapeutic Level V: Case Report, Expert Opinion

APA, Harvard, Vancouver, ISO, and other styles

3

Beenken, Karen E., Laura Bradney, William Bellamy, Robert A. Skinner, Sandra G. McLaren, M. Johannes Gruenwald, Horace J. Spencer, James K. Smith, Warren O. Haggard, and Mark S. Smeltzer. "Use of Xylitol To Enhance the Therapeutic Efficacy of Polymethylmethacrylate-Based Antibiotic Therapy in Treatment of Chronic Osteomyelitis." Antimicrobial Agents and Chemotherapy 56, no. 11 (September 4, 2012): 5839–44. http://dx.doi.org/10.1128/aac.01127-12.

Full text

Abstract:

ABSTRACTUsing a rabbit model of postsurgical osteomyelitis, we demonstrate that incorporation of xylitol into polymethylmethacrylate (PMMA) bone cement enhances the elution of daptomycin underin vivoconditions. We also demonstrate that this can be correlated with an improved therapeutic outcome in the treatment of a chronic bone infection following surgical debridement.

APA, Harvard, Vancouver, ISO, and other styles

4

Iwasaki, Yasuhiko. "Bone Mineral Affinity of Polyphosphodiesters." Molecules 25, no. 3 (February 10, 2020): 758. http://dx.doi.org/10.3390/molecules25030758.

Full text

Abstract:

Biomimetic molecular design is a promising approach for generating functional biomaterials such as cell membrane mimetic blood-compatible surfaces, mussel-inspired bioadhesives, and calcium phosphate cements for bone regeneration. Polyphosphoesters (PPEs) are candidate biomimetic polymer biomaterials that are of interest due to their biocompatibility, biodegradability, and structural similarity to nucleic acids. While studies on the synthesis of PPEs began in the 1970s, the scope of their use as biomaterials has increased in the last 20 years. One advantageous property of PPEs is their molecular diversity due to the presence of multivalent phosphorus in their backbones, which allows their physicochemical and biointerfacial properties to be easily controlled to produce the desired molecular platforms for functional biomaterials. Polyphosphodiesters (PPDEs) are analogs of PPEs that have recently attracted interest due to their strong affinity for biominerals. This review describes the fundamental properties of PPDEs and recent research in the field of macromolecular bone therapeutics.

APA, Harvard, Vancouver, ISO, and other styles

5

Anagnostakos, Konstantinos. "Therapeutic Use of Antibiotic-loaded Bone Cement in the Treatment of Hip and Knee Joint Infections." Journal of Bone and Joint Infection 2, no. 1 (January 1, 2017): 29–37. http://dx.doi.org/10.7150/jbji.16067.

Full text

Abstract:

Abstract. The use of antibiotic-loaded cement spacers is an established method in the management of periprosthetic hip and knee joint infections. Despite inconsistencies among published studies, data shows that infection control rates exceed 90% with two-stage exchange arthroplasty. The present work reviews the current literature about antibiotic-loaded cement spacers and concentrates on the indications for spacer implantation, spacer production details, antibiotic impregnation, pharmacokinetic properties, clinical success, mechanical complications, and systemic safety.

APA, Harvard, Vancouver, ISO, and other styles

6

Kinne, Raimund W., Francesca Gunnella, Elke Kunisch, Sascha Heinemann, Berthold Nies, Stefan Maenz, Victoria Horbert, et al. "Performance of Calcium Phosphate Cements in the Augmentation of Sheep Vertebrae—An Ex Vivo Study." Materials 14, no. 14 (July 12, 2021): 3873. http://dx.doi.org/10.3390/ma14143873.

Full text

Abstract:

Oil-based calcium phosphate cement (Paste-CPC) shows not only prolonged shelf life and injection times, but also improved cohesion and reproducibility during application, while retaining the advantages of fast setting, mechanical strength, and biocompatibility. In addition, poly(L-lactide-co-glycolide) (PLGA) fiber reinforcement may decrease the risk for local extrusion. Bone defects (diameter 5 mm; depth 15 mm) generated ex vivo in lumbar (L) spines of female Merino sheep (2–4 years) were augmented using: (i) water-based CPC with 10% PLGA fiber reinforcement (L3); (ii) Paste-CPC (L4); or (iii) clinically established polymethylmethacrylate (PMMA) bone cement (L5). Untouched (L1) and empty vertebrae (L2) served as controls. Cement performance was analyzed using micro-computed tomography, histology, and biomechanical testing. Extrusion was comparable for Paste-CPC(-PLGA) and PMMA, but significantly lower for CPC + PLGA. Compressive strength and Young’s modulus were similar for Paste-CPC and PMMA, but significantly higher compared to those for empty defects and/or CPC + PLGA. Expectedly, all experimental groups showed significantly or numerically lower compressive strength and Young’s modulus than those of untouched controls. Ready-to-use Paste-CPC demonstrates a performance similar to that of PMMA, but improved biomechanics compared to those of water-based CPC + PLGA, expanding the therapeutic arsenal for bone defects. O, significantly lower extrusion of CPC + PLGA fibers into adjacent lumbar spongiosa may help to reduce the risk of local extrusion in spinal surgery.

APA, Harvard, Vancouver, ISO, and other styles

7

Amaral, Cleriston Silva dos Santos, Amanda Felix Gonçalves Tomaz, Igor José de Oliveira Campos, Eros Ruan de Medeiros, João Victor Freire de Paula, Evaldo Henrique Pessoa da Costa, Amanda Feitoza da Silva, Fellipe Moraes Pereira Figueiredo, and Ana Paula Araújo Teixeira. "Current concepts related to the use of bioceramic materials in Dentistry." Research, Society and Development 9, no. 12 (December 26, 2020): e34191211277. http://dx.doi.org/10.33448/rsd-v9i12.11277.

Full text

Abstract:

Endodontics is the specialty that covers the control of inflammation of the root canal, the etiology, diagnosis, prevention and therapeutic intervention of diseases associated with the pulp. The objective of the present study is to highlight the current concepts related to the use of bioceramic materials in dentistry. This is a literature review article, developed through a bibliographic survey in the databases Medline, PubMed, Scielo and Periodicos CAPES. The present study showed a gradual increase in research related to bioceramic cements, which may attribute this interest to the importance of having a constant search for improvement of the techniques and materials used to recover oral health. In addition, a broad clinical applicability of these materials in Endodontics was highlighted, due to the evidence found regarding the advantageous properties, such as their excellent biocompatibility, ability to bond to dentin, good radiopacity, better handling conditions, appropriate setting time, bactericidal activity, bioactivity and still, do not cause stains in dental structures, characteristics sought for a restorative material to be efficient.

APA, Harvard, Vancouver, ISO, and other styles

8

Ntalos, D., M. Priemel, C. Schlickewei, D. M. Thiesen, J. M. Rueger, and A. S. Spiro. "Therapeutic Management of a Substantial Pelvic Aneurysmatic Bone Cyst Including the Off-Label Use of Denosumab in a 35-Year-Old Female Patient." Case Reports in Orthopedics 2017 (2017): 1–5. http://dx.doi.org/10.1155/2017/9125493.

Full text

Abstract:

Aneurysmal bone cysts (ABC) are benign bone tumors, which are highly vascularized. The main course of treatment is curettage followed by bone grafting or cement insertion. Still recurrence remains a main problem for patients. Denosumab is a monoclonal antibody, which acts as an inhibitor of the RANK/RANKL pathway, diminishing bone turnover. Recent case reports have shown that Denosumab can be a promising therapeutic agent for people suffering from therapy-resistant ABC. We report the case of a 35-year-old female patient presenting with a pronounced ABC of the pelvis. Since the tumor was inoperable, Denosumab was administered, leading to a significant shrinkage of the lesion, which allowed surgical intervention. Upon recurrence, Denosumab was restarted putting the patient once more into remission. Follow-up was four years overall with a clinical and radiological stable disease for fifteen months after final discontinuation of the monoclonal antibody. Therefore, our case further underlines the potential of Denosumab in the treatment of ABC.

APA, Harvard, Vancouver, ISO, and other styles

9

Kerry, Ghassan, Claus Ruedinger, and Hans-Herbert Steiner. "Cement embolism into the venous system after pedicle screw fixation: case report, literature review, and prevention tips." Orthopedic Reviews 5, no. 3 (September 12, 2013): 24. http://dx.doi.org/10.4081/or.2013.e24.

Full text

Abstract:

The strength of pedicle screws attachment to the vertebrae is an important factor affecting their motion resistance and long term performance. Low bone quality, <em>e.g</em>. in osteopenic patients, keeps the screw bone interface at risk for subsidence and dislocation. In such cases, bone cement could be used to augment pedicle screw fixation. But its use is not free of risk. Therefore, clinicians, especially spine surgeons, radiologists, and internists should become increasingly aware of cement migration and embolism as possible complications. Here, we present an instructive case of cement embolism into the venous system after augmented screw fixation with fortunately asymptomatic clinical course. In addition we discuss pathophysiology and prevention methods as well as therapeutic management of this potentially life-threatening complication in a comprehensive review of the literature. However, only a few case reports of cement embolism into the venous system were published after augmented screw fixation.

APA, Harvard, Vancouver, ISO, and other styles

10

Montgomery, Corey, Cory Couch, Cynthia Emory, and Richard Nicholas. "Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options." Journal of Knee Surgery 32, no. 04 (November 16, 2018): 331–36. http://dx.doi.org/10.1055/s-0038-1675815.

Full text

Abstract:

AbstractGiant cell tumor of bone is a benign albeit aggressive tumor commonly affecting the bones of the knee. Patients with these tumors present with pain, swelling, and inability to bear weight on the involved extremity. These destructive tumors typically arise in the metaphyseal region of the long bones in individuals in the second, third, and fourth generations of life. Histologically, the multinucleated giant cells are the hallmark of the lesion, easily recognized on histological review, which recently have become therapeutic targets for medical management of the disease. For decades, surgical management has been the primary treatment for giant cell tumor of the bone. Some tumors can be treated with excision and filling of the osseous void with bone cement or allograft. This is an effective treatment option with a low to moderate risk of local recurrence while preserving limb function. For more destructive tumors, wide excision and reconstruction with prosthetic, structural allograft or combined allograft prosthetic components are utilized. Advances in medical management of the disease have also demonstrated promise as an effective treatment; however, its use has usually been limited to the treatment of metastatic disease, recurrent disease or when advanced local disease would require surgical treatment felt to be overly morbid.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "BONE CEMENTS/therapeutic use"

1

Lam, Wing-moon Raymond, and 林榮滿. "Strontium apatite nanoparticle bioactive bone cement: from biomaterial development to pre-clinicalevaluations." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B43759968.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Liu, Wai-ching, and 廖惠清. "Strontium incorporated materials in orthopaedics: gentamicin release in bone cement and scaffolds with highmechanical properties for tissue engineering." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B47234672.

Full text

Abstract:

　　　Strontium (Sr) is not only widely studied for its compound as a drug for treating osteoporosis, but there is also a growing interest of its addition in orthopaedic biomaterials. Over the years, the development of orthopaedic biomaterials has already advanced to a new era in the search of resorbable and/or bioactive materials. Due to its anabolic and anti-resportive properties of Sr on bone regeneration as a drug, strontium has been extensively investigated for its potential in other orthopaedic applications. The purposes of this study were to investigate strontium containing hydroxyapatite (Sr-HA) bone cement for the delivery of gentamicin and the effects of Sr incorporation in coral and borosilicate glass as bone engineering scaffolds. 　　　　　　Three types of Sr incorporated materials are reported here, in which these include an applied study of the drug elution property of previously published bone cement and two initial studies of the biological properties of newly developed coral and borosilicate scaffolds. Firstly, the gentamicin release, bioactivity and mechanical property of bioactive bone cement filler based on Sr-HA were compared to a commercially available gentamicin-loaded poly(methyl methacrylate) (PMMA). Over the study period of 30 days, the cumulative gentamicin release from Sr-HA bone cement was much greater than PMMA bone cement (+ 34%); better bioactivity of Sr-HA was also confirmed with the apatite formation after simulated body fluid immersion. Goniopora, a highly interconnected porous coral, was hydrothermally converted to coralline hydroxyapatite (CHA) or coated with hydroxyapatite and incorporated with Sr. As the first report of incorporating Sr into coral with the structure remained, about 4-16% Sr was detected on CHA. Sr-HA coated coral was studied in vitro and in vivo (ovariectomized rat model) resulting in better cell proliferation and higher scaffold volume retention (+40%). Finally, the development of Sr incorporated borosilicate (SrB) glass scaffold explored a new material for bone tissue engineering, but more importantly, it introduced a phenomenal idea of the stimulatory effect of a local alkaline microenvironment on bone regeneration. Detections of an exceedingly high pH (~ pH 8.6) condition on the material surface and release of Sr, Si and B ions during the degradation of scaffold SrB were confirmed to stimulate osteoblasts and facilitate apatite formation. Although new bone was observed on both scaffolds, higher bone area/tissue area (B.Ar/T.Ar) on scaffold SrB indicated more new bone formation over borosilicate scaffold without Sr addition. 　　　　　　The significance of this study is to explore and develop three orthopaedic biomaterials advancing the stimulatory effects of Sr on bone regeneration. The drug elution properties of Sr-HA bone cement provides a fascinating alternative for treating osteomyelitis. Furthermore, by incorporating Sr into CHA and borosilicate scaffold, it brings out the importance on the readiness of the Sr release of the materials in order to deliver the stimulatory effects. Subsequently, a localized pH micro-environment arisen by material degradation is emphasized as a controlling factor in bone regeneration on biomaterials.
published_or_final_version
Orthopaedics and Traumatology
Doctoral
Doctor of Philosophy

APA, Harvard, Vancouver, ISO, and other styles

3

Ni, Guoxin, and 倪國新. "In vivo studies of strontium-containing hydroxyapatite bioactive bone cement in primary and revision hip replacement." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2006. http://hub.hku.hk/bib/B36596577.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Wang, Ting, and 王挺. "A comparative study on initial prothesis stability fixed by strontium-containing hydroxyapatite comparing with polymethyl methacrylate bonecement." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B44193269.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Cabrita, Henrique Antonio Berwanger de Amorim. ""Estudo comparativo do tratamento das artroplastias infectadas do quadril sem e com o uso do espaçador de cimento com antibiótico"." Universidade de São Paulo, 2004. http://www.teses.usp.br/teses/disponiveis/5/5140/tde-04102005-113802/.

Full text

Abstract:

Em um estudo prospectivo sobre o tratamento das artroplastias de quadril infectadas, com perdas ósseas e fístulas ativas, 25 pacientes foram tratados em dois tempos e 36 pacientes foram tratados em dois tempos com espaçador de cimento impregnado com vancomicina. O acompanhamento médio foi de dois anos e onze meses. A taxa de recidiva infecciosa foi de 29,2% nos tratados em dois tempos e de 8,8% nos tratados com espaçador. O Escore de Harris para Quadril médio passou de 19,3 para 69,0 pontos nos casos tratados em dois tempos e de 19,7 para 72,2 pontos nos pacientes tratados com espaçador. Ao final do estudo, 86,1% dos tratados com espaçador e em 33,3% dos tratados em dois tempos tinham próteses em bom funcionamento e sem infecção. O espaçador de cimento com antibiótico é o tratamento de escolha nas próteses infectadas de quadril
We report a prospective study of 61 patients with chronically deep infected hip replacements with actively discharging sinuses, treated with a two-stage revision protocol, with and without a cement spacer impregnated with vancomycin. The average follow-up was two years and eleven months. Twenty-five patients were treated without a spacer and seven had recurrence of infection. Thirty-three patients were treated with a spacer and three had recurrence of infection. The average Harris Hip score increased from 19,3 to 69,0 on the non-spacer patients and from 19,7 to 75,2 on the spacer group. At the end of the study, the success rate was 86,1% for the spacer group and 33,3% for the non-spacer group. The use of the spacer increased the results of the two-stage chronic infected hip replacements

APA, Harvard, Vancouver, ISO, and other styles

6

Goto, Koji. "Bioactive bone cements containing nano-sized titania particles for use as bone substitutes." Kyoto University, 2006. http://hdl.handle.net/2433/143869.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Gonçalves, Luís Pedro Valente. "Ready to use injectable bone substitutes." Master's thesis, Universidade de Aveiro, 2016. http://hdl.handle.net/10773/17462.

Full text

Abstract:

Mestrado em Materiais e Dispositivos Biomédicos
In recent years, the development and innovation of new bone substitutes has revolutionized the lives of millions of patients. The aim of this work is the development and characterization of a bioactive, injectable and ready-to-use system (also called putty or premixed cement) for bone regeneration. The solid phase is constituted by beta-tricalcium phosphate (β-TCP), FastOs® bioglass (FastOs® BG) and monocalcium phosphate monohydrate (MCPM) powders, while the liquid phase comprises glycerol (G). The synthesis of β-TCP powder was obtained by precipitation reactions followed by heat-treatment; FastOs® BG was obtained by melt-quenching. The characterization of the obtained powders was made through X-ray diffraction (XRD) and measurement of the mean particle sizes and particle size distribution. The putty was prepared by mixing the solid and liquid phases and placed in syringes with a screw cap. Regarding clinical application, injectability, setting time (ST) and mechanical strength were investigated to characterize the putty. Structural analyses of the putty were also performed by XRD, Fourier Tranform Infrared Spectroscopy (FTIR) and Scanning Electron Microscopy (SEM). The putty has a solid/liquid weight ratio (S/L) of 3.3, mean ST of ~25 min, ~96% of injectability and a maximum compressive strength of 6 MPa. Therefore, the putty exhibited excellent injectability results, absence of filter pressing effect and acceptable mechanical properties. The structural analysis of the hardened cements revealed the formation of monetite crystals covered by an amorphous apatitic layer after immersion in PBS and water. The results are encouraging and support the conclusion that ready-to-use injectable bone substitutes have excellent handling properties to be used clinically. In accordance with the Directive 93/42/EEC the putty is considered a class III medical device. In order to pave the way towards its commercial release and in order to meet the essential requirements set out in Annex I of the Directive 93/42/EEC, a clinical evaluation has been carried out.
Nos últimos anos, o desenvolvimento e a inovação de novos substitutos ósseos tem revolucionado a vida de milhões de doentes. O objetivo deste trabalho é o desenvolvimento e caracterização de um sistema bioativo, injectável e pronto-a-usar (putty) para regeneração óssea. A fase sólida é constituída por pós de fosfato tricálcico beta (β-TCP), biovidro FastOs (FastOs®BG) e fosfato monocálcico monohidratado (MCPM), enquanto a fase líquida é o glicerol (G). A síntese dos pós de β-TCP foi obtida por reações de precipitação seguida de tratamento térmico; os pós de FastOs®BG foram obtidos por fusão e arrefecimento em água fria (fritagem) (melt-quenching). A caracterização dos pós foi feita por difracção de raios-X (XRD) e medição dos tamanhos de partícula. O sistema injectável pronto-a-usar foi preparado através da mistura das fases sólida e líquida e colocado em seringas seladas com tampa roscada. Do ponto de vista de aplicação clínica, o sistema foi caracterizado tendo em conta a sua injectabilidade, tempo de presa (setting time, ST) e resistência mecânica. A análise estrutural do sistema também foi realizada, através de XRD, espectroscopia de infravermelho com transformada de Fourier (FTIR) e microscopia eletrónica de varrimento (SEM). O sistema injectável pronto-a-usar tem uma razão em peso sólido/líquido (S/L) de 3,3, um ST médio de ~25 min, ~96% de injectabilidade, e 6 MPa de resistência máxima à compressão. Deste modo, o sistema injetável demonstrou excelentes resultados de injectabilidade, tendo-se verificado ainda a ausência do efeito de filter pressing e propriedades mecânicas aceitáveis. A análise estrutural dos cimentos endurecidos revelou a formação de cristais de monetite recobertos por uma camada apatítica amorfa após imersão em PBS e em água. Os resultados obtidos são promissores e permitem concluir que o sistema injetável pronto-a-usar possui excelentes propriedades de manipulação do ponto de vista clínico. De acordo com a Directiva 93/42/CEE o sistema injetável é considerado um dispositivo médico de classe III. Com o objectivo de contribuir para o seu processo de lançamento comercial e seguindo os requisitos essenciais estabelecidos no anexo I da Directiva 93/42/CEE foi elaborado um relatório tendo em conta a avaliação clínica do sistema injectável.

APA, Harvard, Vancouver, ISO, and other styles

8

Brook, Ian Michael. "Evaluation of glass-ionomer cements for use as bone substitutes with reference to their value for treatment of atrophic alveolar bone." Thesis, University of Sheffield, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.695353.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Roberts, Jacintha. "Studies on bisphosphonate elution from orthopaedic implants." Thesis, McGill University, 2008. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=112582.

Full text

Abstract:

In a 6-week rat model it was demonstrated that a small dose of peri-implant zoledronic acid (ZA) increased local bone formation 3-fold compared with controls. Ancillary in vitro studies using 14C-labeled ZA implant doses demonstrated biphasic elution profiles for implants coated with hydroxyapatite; complete ZA release occurred within one to three weeks in serum compared with only 60% ZA release after 12 weeks in water. Implants without hydroxyapatite coating showed more burst-type release profiles and full ZA elution within 24 hours of hydration in serum or water. Canine studies at 6 weeks using implants with 14C-labeled ZA showed that the compound remained localized, with the greatest ZA concentration immediately adjacent to the implant. Although there was evidence of skeletal ZA distribution via diffusion into the circulation, the levels were two orders of magnitude less than at the implant site.

APA, Harvard, Vancouver, ISO, and other styles

10

Abbah, Sunny Akogwu. "Towards an injectable bone graft substitute: evaluation of sodium alginate microcapsules for bone tissueengineering." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2006. http://hub.hku.hk/bib/B39329951.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "BONE CEMENTS/therapeutic use"

1

Whitfield, James F. Growing bone. 2nd ed. Austin, Tex: Landes Bioscience, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Whitfield, James F. Growing bone. 2nd ed. Austin, Tex: Landes Bioscience, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Whitfield, James F. Growing bone. 2nd ed. Austin, Tex: Landes Bioscience, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Prevention of bone metastases. Heidelberg: Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Pak, Yong-bŏm. Hanʼgugin esŏ hŭnhan kangjiksŏng chʻŏkchʻuyŏm ŭi tʻŭkchingjŏgin chʻŏkchʻu kangjik ŭi pyŏngin e issŏsŏ bone morphogenetic proteins wa transforming growth factor-[beta] ŭi yŏkhal =: Pathogenic role of bone morphogenetic proteins and transforming growth factor-[beta] in syndesmophytosis of ankylosing spondylitis. [Seoul]: Pogŏn Pokchibu, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

McKay, William F. The rhBMP-2 reference guide. St. Louis, Mo: Quality Medical Pub., 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Gary, Gagliardi, and Fuerst Mark, eds. The shark cartilage alternative: For bone and joint health. New Canaan, Conn: Keats Pub., 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Fleisch, Herbert. Bisphosphonates in bone disease: From the laboratory to the patient. Bern: H. Fleish, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Bisphosphonates in bone disease: From the laboratory to the patient. 4th ed. San Diego: Academic Press, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Bisphosphonates in bone disease: From the laboratory to the patient. 3rd ed. New York: Parthenon Pub. Group, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "BONE CEMENTS/therapeutic use"

1

Ruiz, A. L., and J. G. Brown. "The Use of the Kent Hip in Fractures." In Bone Cements and Cementing Technique, 109–15. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-59478-6_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Wolff, Julius. "On the Remodelling Force and Its Therapeutic Use." In The Law of Bone Remodelling, 85–87. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-71031-5_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Copp, D. Harold. "Recent Trends in the Use of Bone Regulatory Factors as Therapeutic Agents." In Bone Regulatory Factors, 269–84. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4757-1508-8_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Elgazzar, Abdelhamid H. "Therapeutic Use of Radionuclides in Bone and Joint Disease." In Orthopedic Nuclear Medicine, 387–415. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56167-7_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Elgazzar, Abdelhamid H. "Therapeutic Use of Radionuclides in Bone and Joint Disease." In Orthopedic Nuclear Medicine, 211–27. Berlin, Heidelberg: Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18790-2_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Nimer, Stephen D., and Richard E. Champlin. "Therapeutic use of hematopoietic growth factors in bone marrow transplantation." In Cancer Treatment and Research, 141–64. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4613-1493-6_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

F. El-Maghraby, Hesham, and Yaser E. Greish. "Preparation, Structural Characterization, and Biomedical Applications of Gypsum-Based Nanocomposite Bone Cements." In Novel Nanomaterials. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.94317.

Full text

Abstract:

Hard tissues are natural nanocomposites comprising collagen nanofibers that are interlocked with hydroxyapatite (HAp) nanocrystallites. This mechanical interlocking at the nanoscale provides the unique properties of hard tissues (bone and teeth). Upon fracture, cements are usually used for treatment of simple fractures or as an adhesive for the treatment of complicated fractures that require the use of metallic implants. Most of the commercially available bone cements are polymer-based, and lack the required bioactivity for a successful cementation. Besides calcium phosphate cements, gypsum is one of the early recognized and used biomaterials as a basi for a self-setting cementation. It is based on the controlled hydration of plaster of Paris at room temperature and its subsequent conversion to a self-setting solid gypsum product. In our work, we have taken this process further towards the development of a set of nanocomposites that have enhanced bioactivity and mechanical properties. This chapter will outline the formation, characterization, and properties of gypsum-based nanocomposites for bone cement applications. These modified cements can be formulated at room temperature and have been shown to possess a high degree of bioactivity, and are considered potential candidates for bone fracture and defect treatment.

APA, Harvard, Vancouver, ISO, and other styles

8

"7 Properties of Bone Cements and Vertebral Fill Materials: Implications for Clinical Use in Image-Guided Therapy and Vertebral Augmentation." In Vertebral Augmentation, edited by Douglas P. Beall. Stuttgart: Georg Thieme Verlag, 2020. http://dx.doi.org/10.1055/b-0040-175456.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kanellias, Nikolaos, Maria Gavriatopoulou, and Evangelos Terpos. "Antibody Therapies for Multiple Myeloma." In Multiple Myeloma [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.98656.

Full text

Abstract:

Multiple Myeloma (MM) is characterized by the abberant proliferation and expansion of plasma cells in the Bone marrow. Despite the broad use of proteasome inhibitors and IMiDs, Multiple Myeloma remains an incurable disease. The introduction of Monoclonal antibodies, along with bi-specific antibodies and check point inhibitors, has significantly enhanced the armamentarium of available therapeutic options in the relapsed setting. The incorporation of the above-mentioned novel agents in triplet or quadruplet therapeutic regimens has led to significant prolongation of overall survival (OS) and progression free survival (PFS), without adding significant toxicity. Anti-CD38 monoclonal antibodies has become the cornerstone of antimyeloma therapy in both the newly diagnosed and relapsed setting.

APA, Harvard, Vancouver, ISO, and other styles

10

Mazziotti, Gherardo, Andrea Giustina, Ernesto Canalis, and John P. Bilezikian. "Glucocorticoid-induced osteoporosis." In Oxford Textbook of Endocrinology and Diabetes, 754–59. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199235292.003.0497.

Full text

Abstract:

Synthetic glucocorticoids are used in a wide variety of disorders including autoimmune, pulmonary, and gastrointestinal diseases, as well as in patients following organ transplantation and with malignancies. Although the indications for glucocorticoids in these various conditions are clear, their use is fraught with a host of potential side effects. In particular, glucocorticoids are detrimental to bone and glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis (1). Despite the fact that glucocorticoids can cause bone loss and fractures, many patients receiving or initiating long-term glucocorticoid therapy are not evaluated for their skeletal health. Furthermore, patients often do not receive specific preventive or therapeutic agents when indicated. New knowledge of the pathophysiological mechanisms underlying GIO has been accompanied by the availability of effective strategies to prevent and treat GIO (1).

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "BONE CEMENTS/therapeutic use"

1

Agarwal, A. K., M. Kodigudla, D. Desai, A. D. Jones, B. Lin, V. K. Goel, and B. Schlossber. "Biomedical Evaluation of Polymerized Biodegradable Cement vs. PMMA Cement in Kyphoplasty for Vertebral Compressive Fractures." In ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14230.

Full text

Abstract:

Kyphoplasty/vertebroplasty procedures traditionally use PMMA to treat the fractured vertebrae due to its mechanical properties. However, with time the bone erodes around the cement due to osteoporosis and inhibited bone remodeling due to the cyotoxicity of PMMA (1). The exothermic reaction of PMMA is also responsible for thermal necrosis and can cause complications in cases of extravasation (1; 2; 3). Lastly, PMMA is not bioactive and will not be reabsorbed (1; 2; 3). Thus, alternative cements with similar mechanical strengths are being explored. Calcium phosphate cements (CaP) have been explored due to their bioactive and non-thermal properties (3; 4). Despite these advantages, there are reservations of traditional CaP cements due to deficiencies in mechanical properties (1; 4). We evaluated new polymerized calcium phosphate (pCaP) cement which is not brittle like traditional CaP cements. Mechanical properties of vertebral bodies augmented with either PMMA or pCaP after fracture were determined.

APA, Harvard, Vancouver, ISO, and other styles

2

Paliwal, Manish, Brian Kern, and D. Gordon Allan. "Evaluation of the Effect of Cement Viscosity on Cement Mantle in Total Knee Arthroplasty." In ASME 2008 International Mechanical Engineering Congress and Exposition. ASMEDC, 2008. http://dx.doi.org/10.1115/imece2008-67967.

Full text

Abstract:

Aseptic loosening of the tibial implant remains one of the major reasons of failure in Total Knee Arthroplasty (TKA). The cement viscosity at the time of application to the bone is of great importance to ensure a long-term success of the arthroplasty, as it influences the cement penetration and stability of the prosthesis. Currently, there are number of cements available with a wide range of viscosities and set times. High viscosity faster-setting cements may significantly reduce operating room times. However, the concern is that this positive feature may be at the expense of decreased penetration into the bone, and hence reduced stability of the construct. The use of four cement types ((DePuy II (DePuy Inc. Warsaw, IN), Endurance (DePuy Inc. Warsaw, IN), Simplex-P (Stryker Corp Kalamazoo, MI), and Palacos (Zimmer, Inc, Warsaw, IN)) were compared and evaluated during TKA using surrogate tibiae, with respect to the depth of cement penetration according to the Knee Society Total Knee Arthroplasty Roentgenographic Evaluation System. On radiographic analysis of the implanted surrogate tibiae, it was found that Simplex had the maximum commulative penetration of 19.2 mm in seven zones in Mediolateral view, and 12.7 mm in three zones in anteroposterior view. In zone seven, the difference was statistically significant when comparing Simplex with Palacos (11 mm vs 4.6 mm, two-tailed P value = 0.035), somewhat significant with Depuy 2 (11 mm vs 6 mm, two tailed P value = 0.08), but the different was not significant when compared with Endurance (11 mm vs 10 mm, two-tailed P value = 0.6345). In Zone 5, the difference was statistically significant with Simplex vs Endurance (0.3 mm vs 2.2 mm, P = 0.028), and with Simplex vs Depuy 2 (0.3 mm vs 2.17 mm, P = 0.012). This study enhances the understanding of the relation between cement viscosities and cement penetration into cancellous bone during TKA.

APA, Harvard, Vancouver, ISO, and other styles

3

Chumacero-Polanco, Erik A., and James Yang. "Fall Prevention Therapies for Individuals With Stroke: A Survey." In ASME 2017 International Design Engineering Technical Conferences and Computers and Information in Engineering Conference. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/detc2017-67456.

Full text

Abstract:

Stroke basically consists in brain-cells death due to lack or excess of blood. Stroke has many important consequences and falls are one of the most concerning. Falls can produce several injures from minor lacerations to fractures and death. It has been found that balance and gait impairments after stroke are important risk factors for fall. Hence, improving balance and gait ability in stroke survivors can significantly reduce falls rate. In this literature review, we review the main characteristic and the therapeutic results of different therapeutic interventions aimed at improving balance and walking ability. The main therapeutic interventions included are the Bobath therapy, exercise-based interventions, orthotic and assistive devices, modality treatments, alternative therapies, robotic-assisted training, and computational-based interventions. The parameters considered as evidence of balance and/or gait recovery after a specific intervention are: walking speed (WS), cadence, endurance, stride/step length, weight/walking symmetry, and sway. Our main findings are: 1) The wide use of the Bobath concept is not well supported by evidence due to its performance has been found to be inferior to some exercises-based interventions such as walking training; 2) exercises-based interventions were classified as strength and task-specific training. The former improves muscular and bone health, aerobic capability, and prepares the patient to perform a more demanding activity. The latter is designed as a repetitive training of a functional activity, mainly walking, and sit to stand exercises, which improve both gait and balance. Orthotic and assistive devices have effects on balance and gait but only while they are worn or used; 3) robotic assisted walking-training presented similar results to overground or treadmill walking training in terms of walking speed and balance recovery. However, the most important advantage lies on the reduction of burden for therapists; 4) thee most important use of motion analysis is as a tool for identify the causes deficits in a patient and the to design a therapy in accordance; 5) motion synthesis can be used as a tool to answer very specific questions related to capabilities/limitations of a patient. For instance, “what would be the effect of increasing hip-torque capability of a stroke survivor on the walking-symmetry?” The answer to this question would either help to design an exercise/intervention or to discard such intervention due to low impact; 6) some treatments are added to a main therapy to increase its effect on a given parameter. Functional electrical stimulation, which is added to cycling training to improve motion patterns. Biofeedback is used during balance training to reduce weight-asymmetry. And virtual reality and video games are used to increase motivation and permanence of patient on a therapy; 7) we found some alternative or no widely used therapies. Among the most promising we can mention Tai-Chi exercises, which integrates physical and mental activities to improve balance and gait and rhythmic auditory stimulation that improves WS and weight-symmetry; and 8) orthotics devices help to reduce falls by extending the base of support but the effect appears only while they are worn. In general, there is not an ultimate therapy able to fit to every patient. The choice should depend on patient’s goals and conditions. Moreover, falls can not be eliminated but they can be substantially reduced by improving balance and gait.

APA, Harvard, Vancouver, ISO, and other styles

4

McGhee, Paul, Devdas Pai, Sergey Yarmolenko, Jagannathan Sankar, Zhigang Xu, Sudheer Neralla, and Yongjun Chen. "Directional-Tribological Investigation of Magnesium Alloys Under As-Cast and Hot Extrusion Conditions." In ASME 2015 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2015. http://dx.doi.org/10.1115/imece2015-51920.

Full text

Abstract:

In recent years, magnesium (Mg) and its alloy are being studied for their potential use in orthopedic implants with the novel ability to biodegrade after the implant serves its therapeutic function. Pure Mg, by itself, would not be suitable for use in a load-bearing implant application, due to its high corrosion rate and poor tribological properties. However, through proper alloying, this degradable metal is capable of achieving good mechanical properties reasonably similar to bone, a retarded rate of corrosion and enhanced biocompatibility. Previous studies have shown that alloying Mg with aluminum, lithium, rare earth (RE), zinc (Zn), and calcium (Ca) result in lower corrosion rates and enhanced mechanical properties. Despite the growing popularity of Mg and it alloys, there is relatively little information in the literature on their wear performance. In this paper, we report on an investigation of the directional tribological properties of Mg and Mg-Zn-Ca-RE alloy fabricated via two different manufacturing processing routes: as-cast and hot-extruded after casting, with extrusion ratios of 10 and 50. Pure Mg was cast 350°C. After casting, Mg-Zn-Ca-RE alloy was heat-treated at 510°C. Another Mg-Zn-Ca-RE alloy was hot-extruded at 400°C. Dry sliding wear tests were performed on as-cast and hot-extruded pure Mg and Mg-Zn-Ca-RE alloys using a reciprocating test configuration. Wear rate, coefficient of friction and wear coefficient were measured under applied loads ranging from 0.5–2.5N at sliding frequency of 0.2 Hz for 120 cycles, using microtribometery. Wear properties of the extruded specimen were measured in cross-section and longitudinal section. In the longitudinal section studies, wear properties were investigated along the extrusion direction and the transverse direction. Hardness properties were evaluated using microindentation. Cross-section and longitudinal section were indented with a Vickers indenter under applied load of 2.94 N. Alloying and extrusion enhanced the mechanical properties significantly, increased hardness by 80% and wear resistance by 50% compared to pure Mg. Despite the low hardness in both Mg and the Mg alloy cross-sections, the cross-sections for both displayed higher wear resistance compared to the longitudinal section. In the longitudinal section, wear resistance was higher along the transverse direction of the longitudinal section for both Mg and the Mg alloy. The wear coefficient was used to evaluate how the wear behavior of the material varied with respect to alloying, fabrication process, and direction of wear. The wear coefficient of pure Mg decreased as the extrusion ratio increased, thus, increasing the specific wear rate. The opposite behavior was found in the Mg alloy: as the wear coefficient increases, the specific wear rate decreases. The active wear mechanisms observed on the worn surface of Mg were fatigue, abrasive, adhesive and delamination wear. The same wear mechanisms were observed in the Mg alloy except for fatigue wear. Surface microstructure and topographical characterization were conducted using optical microscopy, scanning electron microscopy mechanical stylus profilometry, and optical profilometry.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!